MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WAKID, N.
Right arrow Articles by MANSOUR, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WAKID, N.
Right arrow Articles by MANSOUR, T. E.

Molecular Pharmacology, Vol 1, 53-59, Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics

Factors Influencing the Stability of Heart Phosphofructokinase

NABIL WAKID 1 and TAG E. MANSOUR 1

1 Department of Pharmacology, Stanford University School of Medicine, Palo Alto, California

Phosphofructokinase from the guinea pig heart is an extremely labile enzynme. It becomes more stable in the presence of perchloric acid extracts from the liver. Fructose-1,6-P2 has been identified in these extracts as a potent stabilizer for the enzyme. The stabilizing effects for enzyme activity of the following four groups of compounds were tested: thiol derivatives, hexose phosphate, adenylic nucleotides, and polyvalent inorganic anions. The most potent representatives of these groups are: glutathione or mercaptoethanol, fructose-1,6-P2, ADP or ATP, and phosphate or sulfate anion. A combination of these agents, besides providing complete protection for the enzyme, causes a slight activation during incubation.

Note:
ACKNOWLEDGMENT Supported by Research Grant AI04214 from the National Institute of Allergy and Infectious Diseases, U.S. Public Health Service; Research Career Development Award GM-K3-3848 from the Division of General Medical Sciences, U.S. Public Health Service: and a grant from the Santa Clara County Heart Association.

Submitted on April 20, 1965




This article has been cited by other articles:


Home page
 J. Neurosci.Home page
I. M. Stanford and A. J. Cooper
Presynaptic µ and delta  Opioid Receptor Modulation of GABAA IPSCs in the Rat Globus Pallidus In Vitro
J. Neurosci., June 15, 1999; 19(12): 4796 - 4803.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics